Vivos Therapeutics, Inc. (VVOS): Nasdaq/NYSE listing notice — Vivos receives Nasdaq deficiency notice for stockholders' equity below $2.5M

Vivos Therapeutics, Inc.

Stockholders' equity as of June 30, 2023 was approx. $2.106M, below Nasdaq's $2.5M minimum.
Company has until October 2, 2023 to submit a compliance plan to Nasdaq.
If plan accepted, Nasdaq may grant extension through February 13, 2024.
Failure to regain compliance could lead to delisting; no immediate impact on listing.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

be at least $2,500,000 (the “Minimum Stockholders’ Equity Requirement”). As reported in its Form 10-Q, the Company’s stockholders’ equity as of June 30, 2023 was approximately $2,106,000. The Staff’s notice has no immediate impact on the listing of the Company’s common stock on Nasdaq. In accordance with the Nasdaq Listing Rules, the Company has 45 calendar days,

View on SEC.gov

Browse all listing & compliance notices →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-029522

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.